National Toxicology Program Requests Data on 11 Chemicals

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

RESEARCH TRIANGLE PARK, NC--The National Toxicology Program has requested public input on 11 chemicals recommended for absorption, toxicity, or carcinogenicity studies. It seeks information from completed or ongoing studies, and information on planned studies, as well as current production data, human exposure information, use patterns, and environmental occurrences.

RESEARCH TRIANGLE PARK, NC--The National Toxicology Program has requested public input on 11 chemicals recommended for absorption, toxicity, or carcinogenicity studies. It seeks information from completed or ongoing studies, and information on planned studies, as well as current production data, human exposure information, use patterns, and environmental occurrences.

The compounds include bixin and fenchone, natural products with widespread human exposure; diethylamine, found in some foods; dihydroxyacetone, a component of tanning compounds; isopropylamine, a natural product in foods; pulegone, a flavoring; menthofu-ran, a metabolite of pulegone; and alpha-solanine, a known human toxicant.

Also, alpha-thujone a component of food flavoring additives; triethylamine, a workplace contaminant, and trigonelline, a plant hormone with widespread human exposure through diet.

Information may be submitted until July 27 to William Eastin, NIEHS/NTP, P.O. Box 12233, Research Triangle Park, NC 27709; Fax: 919-541-3687; e-mail: Eastin@NIEHS.

Recent Videos
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.